-
Anlotinib: Selective VEGFR2 Inhibition in Cancer
2026-09-18
The reference study established anlotinib as a highly potent, orally active VEGFR2 inhibitor that suppresses endothelial signaling and tumor angiogenesis in preclinical models. Its key contribution was linking ATP-pocket binding and kinase selectivity to endothelial functional assays, vascular remodeling, and stronger antitumor activity than sunitinib in several mouse models.
-
Dorsomorphin Workflows for AMPK and BMP Research
2026-09-17
Dorsomorphin, also called Compound C, enables reversible interrogation of AMPK-dependent metabolism, autophagy, BMP signaling, and iron homeostasis. This practical guide combines pathway-specific workflows with time-resolved assay design and troubleshooting for more interpretable cell, embryo, and translational studies.
-
AAL-993 VEGF Receptor Inhibitor Workflow
2026-09-17
AAL-993 supports a mechanism-first workflow that separates VEGFR-dependent endothelial effects from direct tumor-cell responses. This guide combines kinase profiling, angiogenesis assays, migration readouts, and glioma-inspired pathway analysis for more interpretable tumor angiogenesis research.
-
GPR30, Spinal CCK+ Neurons, and Neuropathic Pain
2026-09-16
A recent eLife study identifies GPR30 in spinal cholecystokinin-positive neurons as a key contributor to nerve-injury-induced pain. By combining cell-type analysis, synaptic physiology, projection mapping, and chemogenetic circuit manipulation, the work connects spinal estrogen-receptor signaling with AMPA-mediated sensitization and primary sensory cortex input.
-
Remdesivir (GS-5734): From Assay to Evidence
2026-09-16
Remdesivir and GS-5734 are examined through an evidence-to-assay framework spanning coronavirus antiviral research, Ebola models, and emerging RNA viruses. Learn how to interpret potency, treatment timing, formulation, and cross-virus limitations without overextending the data.
-
Fluconazole Workflows for Antifungal Resistance
2026-09-15
Build reproducible Fluconazole assays around ergosterol disruption, concentration-controlled susceptibility testing, and resistance-aware model design. This guide connects routine Candida albicans experiments with resistant Candida auris workflows and shows how to troubleshoot solubility, endpoint variation, and strain-dependent activity.
-
In Vitro Drug Response: Viability and Cell Death
2026-09-15
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-interchangeable dimensions of an in vitro cancer drug response. The framework supports more informative assay design by measuring response magnitude, composition, and timing separately rather than treating a single viability endpoint as a complete pharmacological description.
-
Cisplatin (CDDP): Mechanism and Research Workflow
2026-09-14
Cisplatin (CDDP) is a platinum-based DNA-crosslinking agent that damages guanine-rich DNA and can trigger apoptosis. Its value in cancer research depends on controlled formulation, orthogonal readouts, and careful separation of cell, xenograft, and clinical evidence.
-
Pazopanib Hydrochloride: Smarter In Vitro Assays
2026-09-14
Build more informative cancer assays with Pazopanib Hydrochloride (GW786034), a multi-target inhibitor suited to tumor-cell, angiogenesis, and combination-response studies. The workflow separates growth arrest from cell killing so apparent drug sensitivity is not mistaken for cytotoxicity.
-
Pexidartinib (PLX3397) for TAM Research
2026-09-13
Pexidartinib (PLX3397) enables controlled CSF1R-mediated signaling inhibition to investigate macrophage survival, tumor-supportive phenotypes, and anti-tumor responses. This workflow-oriented guide shows how to pair the compound with SPP1-focused assays while separating macrophage depletion from true phenotypic reprogramming.
-
Cisplatin Workflows for Resistance Research
2026-09-12
Build stronger CDDP experiments by linking DNA crosslinking, apoptosis, oxidative stress, and platinum resistance in one workflow. This guide translates Cisplatin handling into practical cell-based assays, mechanistic validation, and tumor growth inhibition in xenograft models.
-
Shenqi Fuzheng Injection in Glioma: SRC/PI3K/AKT
2026-09-11
The reference study combines network pharmacology with cellular and animal experiments to clarify how Shenqi Fuzheng injection suppresses glioma proliferation and migration. Its results identify SRC/PI3K/AKT signaling as a mechanistic focus while also illustrating the strengths and limits of translating multi-component herbal formulations into molecular pathway models.
-
AMPK–SQSTM1 Feedback Under Metabolic Stress
2026-09-11
The 2024 reference study identifies a reciprocal AMPK–SQSTM1/p62 feedback loop that couples lysosomal stress sensing to coordinated activation of AMPK and NFE2L2/NRF2. Its findings explain how metabolically stressed cancer cells strengthen antioxidant defenses and provide a mechanistic framework for interpreting STK11/LKB1 and KEAP1 pathway alterations in lung cancer.
-
Nintedanib (BIBF 1120) in ATRX-Deficient Glioma
2026-09-10
Nintedanib (BIBF 1120) combines VEGFR, FGFR, and PDGFR blockade in one experimentally tractable molecule for angiogenesis, tumor-cell, and genotype-stratified studies. This workflow connects ATRX status with RTK-inhibitor sensitivity while providing practical guidance for viability, apoptosis, combination, and in vivo experiments.
-
Pazopanib Hydrochloride: From Kinase Maps to Translation
2026-09-10
A translational framework for using Pazopanib Hydrochloride and GW786034 to connect multi-kinase biology with more informative cancer response assays, model selection, and clinically relevant strategy.